Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3B PROBE study of LMWH/edoxaban versus dalteparin in cancer-associated venous thromboembolism
2014-004708-30Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of edoxaban in venous thromboembolism (VTE) and cancer-associated thrombosis (CAT) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Primary composite outcome. Started Mar 2015; status: completed.
02
Drugs
edoxaban
03
Conditions
venous thromboembolism (VTE)cancer-associated thrombosis (CAT)
Beyond the preview
Go deeper on 2014-004708-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004708-30.